{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:40:33Z","timestamp":1792456833415,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R37 CA266270"],"award-info":[{"award-number":["R37 CA266270"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA293766"],"award-info":[{"award-number":["CA293766"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005190","name":"Melanoma Research Alliance","doi-asserted-by":"publisher","award":["1267014"],"award-info":[{"award-number":["1267014"]}],"id":[{"id":"10.13039\/100005190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG-22-167-01-MM"],"award-info":[{"award-number":["RSG-22-167-01-MM"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>An immunosuppressive microenvironment limits therapeutic efficacy in melanoma. Beyond T-cell abundance and function, tumor control depends on T-cell access to malignant cells, yet the vascular mechanisms governing T-cell positioning remain poorly defined. Using RNA sequencing of endothelial cells from tumor cores versus peripheries in a mouse melanoma model, we identified intercellular adhesion molecule-1 (ICAM-1) as a candidate regulator of T-cell localization. During tumor growth, T cells shifted from a balanced core-margin distribution to marked exclusion from the core, particularly in T cell-inflamed tumors. This spatial polarization, less evident in other immune subsets, coincided with high expression of lymphocyte function-associated antigen-1 (LFA-1) on T cells. Endothelial ICAM-1 became enriched at the tumor periphery, where vascular integrity was compromised, with increased vascular leakage and reduced pericyte coverage. ICAM-1 blockade restored T-cell infiltration, enhanced effector activity, and delayed growth of immunogenic tumors, and sensitized an immune-refractory tumor to anti-PD-1 blockade. These findings identify endothelial ICAM-1 as a vascular determinant of T-cell positioning and the ICAM-1\/LFA-1 axis as a modifiable checkpoint to enhance antitumor immunity and immunotherapy efficacy.<\/jats:p>","DOI":"10.1038\/s44321-026-00542-1","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T12:05:53Z","timestamp":1792411553000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Spatial polarization of endothelial ICAM-1 governs T-cell exclusion in melanoma"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3701-8290","authenticated-orcid":false,"given":"Ha-Ram","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn J","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2131-6577","authenticated-orcid":false,"given":"Nashat","family":"Zaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nika P","family":"Kozlov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somnath","family":"Tagore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8013-1275","authenticated-orcid":false,"given":"Lawrence W","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Izar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8401-0078","authenticated-orcid":false,"given":"Minah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,19]]},"reference":[{"key":"542_CR1","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1158\/2326-6066.CIR-25-0744","volume":"14","author":"L Anastacio Da Costa Carvalho","year":"2026","unstructured":"Anastacio Da Costa Carvalho L, Tovbis Shifrin N, Phadke MS, Emmons MF, Pechuan-Jorge X, Mbuga F, Ospina OE, Chow C, Seu L, Rose OL et al (2026) RAS(ON) multiselective inhibition drives antitumor immunity in preclinical models of NRAS-mutant melanoma. Cancer Immunol Res 14:90\u2013106","journal-title":"Cancer Immunol Res"},{"key":"542_CR2","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1158\/0008-5472.CAN-22-0363","volume":"82","author":"A Antoranz","year":"2022","unstructured":"Antoranz A, Van Herck Y, Bolognesi MM, Lynch SM, Rahman A, Gallagher WM, Boecxstaens V, Marine J-C, Cattoretti G, van den Oord JJ et al (2022) Mapping the immune landscape in metastatic melanoma reveals localized cell\u2013cell interactions that predict immunotherapy response. Cancer Res 82:3275\u20133290","journal-title":"Cancer Res"},{"key":"542_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36892-4","volume":"14","author":"X Bai","year":"2023","unstructured":"Bai X, Guo Z-Q, Zhang Y-P, Fan Z-Z, Liu L-J, Liu L, Long L-L, Ma S-C, Wang J, Fang Y et al (2023) CDK4\/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy. Nat Commun 14:1247","journal-title":"Nat Commun"},{"key":"542_CR4","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC et al (2018) Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 24:541\u2013550","journal-title":"Nat Med"},{"key":"542_CR5","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41392-025-02332-6","volume":"10","author":"Z Chao","year":"2025","unstructured":"Chao Z, Mei Q, Yang C, Luo J, Liu P, Peng H, Guo X, Yin Z, Li L, Wang Z (2025) Immunological synapse: structures, molecular mechanisms and therapeutic implications in disease. Signal Transduct Target Ther 10:254","journal-title":"Signal Transduct Target Ther"},{"key":"542_CR6","doi-asserted-by":"publisher","first-page":"6003","DOI":"10.1158\/1078-0432.CCR-20-1523","volume":"26","author":"KD Gray","year":"2020","unstructured":"Gray KD, McCloskey JE, Vedvyas Y, Kalloo OR, Eshaky SE, Yang Y, Shevlin E, Zaman M, Ullmann TM, Liang H et al (2020) PD1 blockade enhances ICAM1-directed CAR T therapeutic efficacy in advanced thyroid cancer. Clin Cancer Res 26:6003\u20136016","journal-title":"Clin Cancer Res"},{"key":"542_CR7","doi-asserted-by":"publisher","first-page":"e55483","DOI":"10.15252\/embr.202255483","volume":"24","author":"MLB Gr\u00f6nloh","year":"2023","unstructured":"Gr\u00f6nloh MLB, Arts JJG, Palacios Mart\u00ednez S, van der Veen AA, Kempers L, van Steen ACI, Roelofs JJTH, Nolte MA, Goedhart J, van Buul JD (2023) Endothelial transmigration hotspots limit vascular leakage through heterogeneous expression of ICAM-1. EMBO Rep 24:e55483","journal-title":"EMBO Rep"},{"key":"542_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-63796-2","volume":"16","author":"M Guo","year":"2025","unstructured":"Guo M, Yuan Z, Jin X, Li X, Deng Y, Zhou S, Niu R, Bae J, Park JB, Shi B et al (2025) Inhibition of ICAM1 diminishes stemness and enhances antitumor immunity in glioblastoma via \u03b2-catenin\/PD-L1 signaling. Nat Commun 16:8642","journal-title":"Nat Commun"},{"key":"542_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25962-0","volume":"12","author":"D Hammerl","year":"2021","unstructured":"Hammerl D, Martens JWM, Timmermans M, Smid M, Trapman-Jansen AM, Foekens R, Isaeva OI, Voorwerk L, Balcioglu HE, Wijers R et al (2021) Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer. Nat Commun 12:5668","journal-title":"Nat Commun"},{"key":"542_CR10","unstructured":"Izar B, Azizi E, Tagore S (2026) NCBI Gene Expression Omnibus GSE308434. (https:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=GSE308434) [DATASET]"},{"key":"542_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce JA, Fearon DT (2015) T cell exclusion, immune privilege, and the tumor microenvironment. Science 348:74\u201380","journal-title":"Science"},{"key":"542_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02150-4","volume":"23","author":"J-H Kang","year":"2024","unstructured":"Kang J-H, Uddin N, Kim S, Zhao Y, Yoo K-C, Kim M-J, Hong S-A, Bae S, Lee J-Y, Shin I et al (2024) Tumor-intrinsic role of ICAM-1 in driving metastatic progression of triple-negative breast cancer through direct interaction with EGFR. Mol Cancer 23:230","journal-title":"Mol Cancer"},{"key":"542_CR13","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1158\/2326-6066.CIR-20-0837","volume":"9","author":"C Kantari-Mimoun","year":"2021","unstructured":"Kantari-Mimoun C, Barrin S, Vimeux L, Haghiri S, Gervais C, Joaquina S, Mittelstaet J, Mockel-Tenbrinck N, Kinkhabwala A, Damotte D et al (2021) CAR T-cell entry into tumor islets is a two-step process dependent on IFN\u03b3 and ICAM-1. Cancer Immunol Res 9:1425\u20131438","journal-title":"Cancer Immunol Res"},{"key":"542_CR14","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","volume":"15","author":"KA Khan","year":"2018","unstructured":"Khan KA, Kerbel RS (2018) Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol 15:310\u2013324","journal-title":"Nat Rev Clin Oncol"},{"key":"542_CR15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0092-8674(00)80095-1","volume":"86","author":"W Kolanus","year":"1996","unstructured":"Kolanus W, Nagel W, Schiller B, Zeitlmann L, Godar S, Stockinger H, Seed B (1996) Alpha L beta 2 integrin\/LFA-1 binding to ICAM-1 induced by cytohesin-1, a cytoplasmic regulatory molecule. Cell 86:233\u2013242","journal-title":"Cell"},{"key":"542_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202204378","volume":"10","author":"S-H Lee","year":"2023","unstructured":"Lee S-H, Kim Y, Jeon B-N, Kim G, Sohn J, Yoon Y, Kim S, Kim Y, Kim H, Cha H et al (2023) Intracellular adhesion molecule-1 improves responsiveness to immune checkpoint inhibitor by activating CD8+ T cells. Adv Sci 10:e2204378","journal-title":"Adv Sci"},{"key":"542_CR17","doi-asserted-by":"publisher","first-page":"8689","DOI":"10.3390\/ijms21228689","volume":"21","author":"A Leong","year":"2020","unstructured":"Leong A, Kim M (2020) The angiopoietin-2 and TIE pathway as a therapeutic target for enhancing antiangiogenic therapy and immunotherapy in patients with advanced cancer. Int J Mol Sci 21:8689","journal-title":"Int J Mol Sci"},{"key":"542_CR18","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/nri2156","volume":"7","author":"K Ley","year":"2007","unstructured":"Ley K, Laudanna C, Cybulsky MI, Nourshargh S (2007) Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 7:678\u2013689","journal-title":"Nat Rev Immunol"},{"key":"542_CR19","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.3389\/fphys.2019.01003","volume":"10","author":"X Liang","year":"2019","unstructured":"Liang X, Arullampalam P, Yang Z, Ming X-F (2019) Hypoxia enhances endothelial intercellular adhesion molecule 1 protein level through upregulation of arginase type II and mitochondrial oxidative stress. Front Physiol 10:1003","journal-title":"Front Physiol"},{"key":"542_CR20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1158\/2159-8290.CD-14-0474","volume":"5","author":"G-Y Liou","year":"2015","unstructured":"Liou G-Y, D\u00f6ppler H, Necela B, Edenfield B, Zhang L, Dawson DW, Storz P (2015) Mutant KRAS-induced expression of ICAM-1 in pancreatic acinar cells causes attraction of macrophages to expedite the formation of precancerous lesions. Cancer Discov 5:52\u201363","journal-title":"Cancer Discov"},{"key":"542_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006401","volume":"11","author":"MM Melssen","year":"2023","unstructured":"Melssen MM, Sheybani ND, Leick KM, Slingluff CL (2023) Barriers to immune cell infiltration in tumors. J Immunother Cancer 11:e006401","journal-title":"J Immunother Cancer"},{"key":"542_CR22","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1016\/j.immuni.2024.09.003","volume":"57","author":"JM Messmer","year":"2024","unstructured":"Messmer JM, Thommek C, Piechutta M, Venkataramani V, Wehner R, Westphal D, Schubert M, Mayer CD, Effern M, Berghoff AS et al (2024) T lymphocyte recruitment to melanoma brain tumors depends on distinct venous vessels. Immunity 57:2688\u20132703.e11","journal-title":"Immunity"},{"key":"542_CR23","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1038\/s41591-024-03249-3","volume":"30","author":"I Nederlof","year":"2024","unstructured":"Nederlof I, Isaeva OI, de Graaf M, Gielen RCAM, Bakker NAM, Rolfes AL, Garner H, Boeckx B, Traets JJH, Mandjes IAM et al (2024) Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial. Nat Med 30:3223\u20133235","journal-title":"Nat Med"},{"key":"542_CR24","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3389\/fonc.2015.00202","volume":"5","author":"PA Ott","year":"2015","unstructured":"Ott PA, Hodi FS, Buchbinder EI (2015) Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: an overview of rationale, preclinical evidence, and initial clinical data. Front Oncol 5:202","journal-title":"Front Oncol"},{"key":"542_CR25","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1158\/0008-5472.CAN-22-2838","volume":"83","author":"H-R Park","year":"2023","unstructured":"Park H-R, Shiva A, Cummings P, Kim S, Kim S, Lee E, Leong A, Chowdhury S, Shawber C, Carvajal R et al (2023) Angiopoietin-2-dependent spatial vascular destabilization promotes T-cell exclusion and limits immunotherapy in melanoma. Cancer Res 83:1968\u20131983","journal-title":"Cancer Res"},{"key":"542_CR26","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1089\/ars.2008.2204","volume":"11","author":"A Rahman","year":"2009","unstructured":"Rahman A, Fazal F (2009) Hug tightly and say goodbye: role of endothelial ICAM-1 in leukocyte transmigration. Antioxid Redox Signal 11:823\u2013839","journal-title":"Antioxid Redox Signal"},{"key":"542_CR27","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aak9670","volume":"9","author":"M Schmittnaegel","year":"2017","unstructured":"Schmittnaegel M, Rigamonti N, Kadioglu E, Cassar\u00e1 A, Wyser Rmili C, Kiialainen A, Kienast Y, Mueller H-J, Ooi C-H, Laoui D et al (2017) Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci Transl Med 9:eaak9670","journal-title":"Sci Transl Med"},{"key":"542_CR28","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1038\/s41588-024-01890-9","volume":"56","author":"C Shiau","year":"2024","unstructured":"Shiau C, Cao J, Gong D, Gregory MT, Caldwell NJ, Yin X, Cho J-W, Wang PL, Su J, Wang S et al (2024) Spatially resolved analysis of pancreatic cancer identifies therapy-associated remodeling of the tumor microenvironment. Nat Genet 56:2466\u20132478","journal-title":"Nat Genet"},{"key":"542_CR29","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1172\/JCI116122","volume":"90","author":"R Shreeniwas","year":"1992","unstructured":"Shreeniwas R, Koga S, Karakurum M, Pinsky D, Kaiser E, Brett J, Wolitzky BA, Norton C, Plocinski J, Benjamin W (1992) Hypoxia-mediated induction of endothelial cell interleukin-1 alpha. An autocrine mechanism promoting expression of leukocyte adhesion molecules on the vessel surface. J Clin Invest 90:2333\u20132339","journal-title":"J Clin Invest"},{"key":"542_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25189-z","volume":"12","author":"R Taftaf","year":"2021","unstructured":"Taftaf R, Liu X, Singh S, Jia Y, Dashzeveg NK, Hoffmann AD, El-Shennawy L, Ramos EK, Adorno-Cruz V, Schuster EJ et al (2021) ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer. Nat Commun 12:4867","journal-title":"Nat Commun"},{"key":"542_CR31","doi-asserted-by":"publisher","unstructured":"Wang A, Geman D, Chitra U, Younes L (2025) Mapping spatial gradients in spatial transcriptomics data with score matching. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.11.24.690257","DOI":"10.1101\/2025.11.24.690257"},{"key":"542_CR32","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/pcmr.12591","volume":"30","author":"J Wang","year":"2017","unstructured":"Wang J, Perry CJ, Meeth K, Thakral D, Damsky W, Micevic G, Kaech S, Blenman K, Bosenberg M (2017) UV-induced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma model. Pigment Cell Melanoma Res 30:428\u2013435","journal-title":"Pigment Cell Melanoma Res"},{"key":"542_CR33","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/s41416-023-02361-4","volume":"129","author":"MM Wang","year":"2023","unstructured":"Wang MM, Coupland SE, Aittokallio T, Figueiredo CR (2023) Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities. Br J Cancer 129:1212\u20131224","journal-title":"Br J Cancer"},{"key":"542_CR34","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41698-024-00671-1","volume":"8","author":"HL Williams","year":"2024","unstructured":"Williams HL, Frei AL, Koessler T, Berger MD, Dawson H, Michielin O, Zlobec I (2024) The current landscape of spatial biomarkers for prediction of response to immune checkpoint inhibition. NPJ Precis Onc 8:178","journal-title":"NPJ Precis Onc"},{"key":"542_CR35","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.3389\/fimmu.2018.02084","volume":"9","author":"A Yanguas","year":"2018","unstructured":"Yanguas A, Garasa S, Teijeira \u00c1, Aub\u00e1 C, Melero I, Rouzaut A (2018) ICAM-1-LFA-1 dependent CD8+ T-lymphocyte aggregation in tumor tissue prevents recirculation to draining lymph nodes. Front Immunol 9:2084","journal-title":"Front Immunol"},{"key":"542_CR36","doi-asserted-by":"publisher","first-page":"1116328","DOI":"10.3389\/fonc.2023.1116328","volume":"13","author":"S Yunger","year":"2023","unstructured":"Yunger S, Geiger B, Friedman N, Besser MJ, Adutler-Lieber S (2023) Modulating the proliferative and cytotoxic properties of patient-derived TIL by a synthetic immune niche of immobilized CCL21 and ICAM1. Front Oncol 13:1116328","journal-title":"Front Oncol"},{"key":"542_CR37","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.devcel.2022.01.002","volume":"57","author":"W Zhang","year":"2022","unstructured":"Zhang W, Zhong W, Wang B, Yang J, Yang J, Yu Z, Qin Z, Shi A, Xu W, Zheng C et al (2022) ICAM-1-mediated adhesion is a prerequisite for exosome-induced T cell suppression. Dev Cell 57:329\u2013343.e7","journal-title":"Dev Cell"},{"key":"542_CR38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2010333118","volume":"118","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Zhang T, Wang Y, Lu D, Du J, Feng X, Zhou H, Liu N, Zhu H, Qin S et al (2021) ICAM-1 orchestrates the abscopal effect of tumor radiotherapy. Proc Natl Acad Sci USA 118:e2010333118","journal-title":"Proc Natl Acad Sci USA"},{"key":"542_CR39","doi-asserted-by":"publisher","first-page":"C1571","DOI":"10.1152\/ajpcell.1997.273.5.C1571","volume":"273","author":"G Z\u00fcnd","year":"1997","unstructured":"Z\u00fcnd G, Uezono S, Stahl GL, Dzus AL, McGowan FX, Hickey PR, Colgan SP (1997) Hypoxia enhances induction of endothelial ICAM-1: role for metabolic acidosis and proteasomes. Am J Physiol 273:C1571\u2013C1580","journal-title":"Am J Physiol"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-026-00542-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44321-026-00542-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-026-00542-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:03:20Z","timestamp":1792454600000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44321-026-00542-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,19]]},"references-count":39,"alternative-id":["542"],"URL":"https:\/\/doi.org\/10.1038\/s44321-026-00542-1","relation":{},"ISSN":["1757-4684"],"issn-type":[{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,19]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}]}}